Gotowa bibliografia na temat „Lentiviral vector”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Lentiviral vector”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Lentiviral vector"
Yew, Chee-Hong Takahiro, Narmatha Gurumoorthy, Fazlina Nordin, Gee Jun Tye, Wan Safwani Wan Kamarul Zaman, Jun Jie Tan i Min Hwei Ng. "Integrase deficient lentiviral vector: prospects for safe clinical applications". PeerJ 10 (12.08.2022): e13704. http://dx.doi.org/10.7717/peerj.13704.
Pełny tekst źródłaLi, Chen, Biao Qian, Zhao Ni, Qinzhang Wang, Zixiong Wang, Luping Ma, Zhili Liu, Qiang Li i Xinmin Wang. "Construction of recombinant lentiviral vector containing human stem cell leukemia gene and its expression in interstitial cells of cajal". Open Life Sciences 15, nr 1 (25.03.2020): 83–91. http://dx.doi.org/10.1515/biol-2020-0010.
Pełny tekst źródłaPerry, Christopher, i Andrea C. M. E. Rayat. "Lentiviral Vector Bioprocessing". Viruses 13, nr 2 (9.02.2021): 268. http://dx.doi.org/10.3390/v13020268.
Pełny tekst źródłaWang, Nan, Narendiran Rajasekaran, Tieying Hou i Elizabeth Mellins. "Comparison of protein expression by different lentiviral vectors (51.12)". Journal of Immunology 188, nr 1_Supplement (1.05.2012): 51.12. http://dx.doi.org/10.4049/jimmunol.188.supp.51.12.
Pełny tekst źródłaNguyen, Tuan Huy, Tatiana Khakhoulina, Andrew Simmons, Philippe Morel i Didier Trono. "A Simple and Highly Effective Method for the Stable Transduction of Uncultured Porcine Hepatocytes Using Lentiviral Vector". Cell Transplantation 14, nr 7 (sierpień 2005): 489–96. http://dx.doi.org/10.3727/000000005783982828.
Pełny tekst źródłaKubo, Shuji, i Kohnosuke Mitani. "A New Hybrid System Capable of Efficient Lentiviral Vector Production and Stable Gene Transfer Mediated by a Single Helper-Dependent Adenoviral Vector". Journal of Virology 77, nr 5 (1.03.2003): 2964–71. http://dx.doi.org/10.1128/jvi.77.5.2964-2971.2003.
Pełny tekst źródłaSakuma, Toshie, Michael A. Barry i Yasuhiro Ikeda. "Lentiviral vectors: basic to translational". Biochemical Journal 443, nr 3 (16.04.2012): 603–18. http://dx.doi.org/10.1042/bj20120146.
Pełny tekst źródłaBreckpot, Karine, David Escors, Frederick Arce, Lucienne Lopes, Katarzyna Karwacz, Sandra Van Lint, Marleen Keyaerts i Mary Collins. "HIV-1 Lentiviral Vector Immunogenicity Is Mediated by Toll-Like Receptor 3 (TLR3) and TLR7". Journal of Virology 84, nr 11 (17.03.2010): 5627–36. http://dx.doi.org/10.1128/jvi.00014-10.
Pełny tekst źródłaPark, Frank. "Lentiviral vectors: are they the future of animal transgenesis?" Physiological Genomics 31, nr 2 (październik 2007): 159–73. http://dx.doi.org/10.1152/physiolgenomics.00069.2007.
Pełny tekst źródłaLucke, Susann, Thomas Grunwald i Klaus Überla. "Reduced Mobilization of Rev-Responsive Element-Deficient Lentiviral Vectors". Journal of Virology 79, nr 14 (lipiec 2005): 9359–62. http://dx.doi.org/10.1128/jvi.79.14.9359-9362.2005.
Pełny tekst źródłaRozprawy doktorskie na temat "Lentiviral vector"
Trimby, Christopher Matthew. "STRATEGIES FOR TARGETING LENTIVIRAL VECTORS". UKnowledge, 2011. http://uknowledge.uky.edu/gradschool_diss/157.
Pełny tekst źródłaIngrao, Dina. "Etude de l'étape d'entrée des vecteurs lentiviraux dérivés du VIH-1 dans les cellules hématopoïétiques humaines". Thesis, Evry-Val d'Essonne, 2013. http://www.theses.fr/2013EVRY0021/document.
Pełny tekst źródłaLentiviral vectors (LV) are used for various gene transfer applications, notably for hematopoietic gene therapy, but methods are lacking to precisely evaluate parameters that control the efficiency of transduction in relation with the entry of vectors into target cells. We adapted a fluorescence resonance energy transfer (FRET)-based HIV-1 fusion assay to measure the entry of non-replicative recombinant LV in various cell types, including primary human hematopoietic stem and progenitor cells, and to quantify the level of transduction of he same initially-infected cells. The assay utilizes recombinant LV containing betalactamase (BLAM)-Vpr chimeric proteins (BLAM-LV) and encoding a truncated form of thelow affinity nerve growth factor receptor (DELTA-NGFR). This LV-based fusion/transduction assay is a dynamic and versatile tool, revealing for instance the extent of lentiviral post-entry restrictions occuring in cells of hematopoietic origin. The assay also shows that transduction enhancers like Vectofusin®-1 or Retronectin® can partially relieve this post-entry block but their effects differ in the way to promote LV entry. Furthermore, our results show that Vectofusin®-1 acts at the entry step by promoting the adhesion and the fusion between lentiviral and cellular membranes. In conclusion, one such assay should be useful to study hematopoietic post-entry restrictions directed against LV and should allow improvements in various LV-based gene therapy protocols
Thomas, Joan Helen. "Studies in gene transfer using pseudotyped lentiviral vector systems". Thesis, University of Cambridge, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.621818.
Pełny tekst źródłaGelinas, Jean-Francois. "Enhancement of lentiviral vector production through alteration of virus-cell interactions". Thesis, University of Oxford, 2016. https://ora.ox.ac.uk/objects/uuid:9921b8b4-e2b5-4eec-9efc-6036765c8d55.
Pełny tekst źródłaZhang, Bing. "Lentiviral vector-mediated gene transfer in vitro and in vivo /". St. Lucia, Qld, 2004. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe18024.pdf.
Pełny tekst źródłaBooth, C. A. "Lentiviral vector mediated gene therapy for X-linked lymphoproliferative disease". Thesis, University College London (University of London), 2012. http://discovery.ucl.ac.uk/1356299/.
Pełny tekst źródłaMacdonald, D. "Lentiviral vector vaccines for T-cell-mediated protection against influenza". Thesis, University College London (University of London), 2014. http://discovery.ucl.ac.uk/1417882/.
Pełny tekst źródłaOakland, Mayumi. "Improving lentiviral vector-mediated gene transfer by understanding cellular barriers". Diss., University of Iowa, 2013. https://ir.uiowa.edu/etd/4709.
Pełny tekst źródłaMekkaoui, Leila. "Lentiviral vector purification using genetically encoded biotin mimic in packaging cell". Thesis, University College London (University of London), 2018. http://discovery.ucl.ac.uk/10053191/.
Pełny tekst źródłaFIRRITO, CLAUDIA. "Targeted Gene Correction and Reprogramming of SCID-X1 Fibroblasts to Rescue IL2RG Expression in iPSC-derived Hematopoietic Cells". Doctoral thesis, Università degli Studi di Milano-Bicocca, 2015. http://hdl.handle.net/10281/94656.
Pełny tekst źródłaGene replacement by integrating vectors has been successfully used to treat several inherited diseases, such as Lysosomal Storage Disorders (LSD), Thalassemia and Primary Immunodeficiencies (PIDs). X-linked Combined Immunodeficiency (SCID-X1) is a fatal monogenic disorder, caused by mutation of the Interleukin 2 Receptor common γ-chain (IL2RG) gene. For SCID-X1, the early clinical studies have clearly shown the therapeutic potential of integrating vector based gene replacement therapy, which achieved efficient lymphoid reconstitution thanks to the selective growth advantage of the genetically modified cells. However, these studies also highlighted the potential risk of insertional mutagenesis due to random integration of the vector into the host cell genome and to unregulated transgene expression, thus calling for the development of safer gene therapy approaches. Here, by combining the Zinc Finger Nuclease (ZFNs) technology to induce site-specific DNA double-strand breaks (DSB) and of Integrase-Defective Lentiviral Vector (IDLV) to deliver a corrective donor template, we exploited Homology Driven Repair (HDR) to correct SCID-X1 mutation in situ, restoring both physiological expression and function of the IL2RG gene . By knocking-in a corrective IL2RG cDNA transgene downstream of its endogenous promoter in B-lymphoblastoid cells, which constitutively express IL2RG, and in primary T-lymphocytes, which requires IL2RG for their survival and growth, we provide evidence of physiologic activity of the gene-edited IL2RG gene. By including an excisable GFP- or a Puromycin Resistance (PuroR) expression cassette downstream of the corrective cDNA, we coupled correction with exogenous selection of corrected SCID-X1 primary fibroblasts, which do not physiologically express IL2RG, and obtained an enriched population of gene-corrected cells. We then reverted this population to pluripotency by using a novel reprogramming vector that expresses OCT4, SOX2, KLF4 and microRNA cluster 302-367 to obtain a potentially unlimited source of gene-corrected induced pluripotent stem cells (iPSC). We thus generated several gene-corrected bona-fide iPSCs, as confirmed by molecular analyses for targeted integration, which were characterized for their pluripotent state. IDLV-mediated transient delivery of the Cre-recombinase resulted in the co-excision of the reprogramming vector together with the selector cassette, thus allowing the generation of several gene-corrected, reprogramming-factor free iPSCs with normal karyotypes. Finally, by differentiating corrected iPSC to T-lymphoid progenitor cells, which are lacking in SCID-X1 patients, and showing a selective growth advantage of those derived from corrected iPSCs, we provide evidence of the functional correction of the IL2RG mutant allele. Overall these data demonstrate the feasibility of our targeted gene editing strategy, which couples gene correction with cell reprogramming to generate disease-free IPSC, thus paving the way for the development of novel and safer therapeutic approaches for SCID-X1.
Książki na temat "Lentiviral vector"
Lentiviral vector systems for gene transfer. Georgetown, TX: Eurekah.com, 2003.
Znajdź pełny tekst źródłaTrono, Didier, red. Lentiviral Vectors. Berlin, Heidelberg: Springer Berlin Heidelberg, 2002. http://dx.doi.org/10.1007/978-3-642-56114-6.
Pełny tekst źródłaEscors, David, Karine Breckpot, Frederick Arce, Grazyna Kochan i Holly Stephenson. Lentiviral Vectors and Gene Therapy. Basel: Springer Basel, 2012. http://dx.doi.org/10.1007/978-3-0348-0402-8.
Pełny tekst źródłaEscors, David. Lentiviral Vectors and Gene Therapy. Basel: Springer Basel, 2012.
Znajdź pełny tekst źródłaMaurizio, Federico, red. Lentivirus gene engineering protocols. Totowa, N.J: Humana Press, 2003.
Znajdź pełny tekst źródłaFederico, Maurizio, red. Lentiviral Vectors and Exosomes as Gene and Protein Delivery Tools. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3753-0.
Pełny tekst źródłaMaurizio, Federico, red. Lentivirus gene engineering protocols. Wyd. 2. New York: Humana Press, 2010.
Znajdź pełny tekst źródłaLentiviral Vector Systems for Gene Transfer (Medical Intelligence Unit, 31). Springer, 2003.
Znajdź pełny tekst źródłaLentiviral Vector Systems for Gene Transfer (Medical Intelligence Unit, 31). Eurekah.com, 2001.
Znajdź pełny tekst źródłaBuchschacher, Gary L. Lentiviral Vector Systems for Gene Transfer (Medical Intelligence Unit, 31). Eurekah.com, 2001.
Znajdź pełny tekst źródłaCzęści książek na temat "Lentiviral vector"
Larochelle, A., K. W. Peng i S. J. Russell. "Lentiviral Vector Targeting". W Current Topics in Microbiology and Immunology, 143–63. Berlin, Heidelberg: Springer Berlin Heidelberg, 2002. http://dx.doi.org/10.1007/978-3-642-56114-6_7.
Pełny tekst źródłaSegura, María Mercedes, Alain Garnier, Yves Durocher, Sven Ansorge i Amine Kamen. "New Protocol for Lentiviral Vector Mass Production". W Lentivirus Gene Engineering Protocols, 39–52. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60761-533-0_2.
Pełny tekst źródłaRamezani, Ali, i Robert G. Hawley. "Strategies to Insulate Lentiviral Vector-Expressed Transgenes". W Lentivirus Gene Engineering Protocols, 77–100. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60761-533-0_5.
Pełny tekst źródłaHan, Shuhong, i Lung-Ji Chang. "Immunity of Lentiviral Vector-Modified Dendritic Cells". W Gene Therapy of Cancer, 245–59. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-561-9_13.
Pełny tekst źródłaChong, Mark S. K., i Jerry Chan. "Lentiviral Vector Transduction of Fetal Mesenchymal Stem Cells". W Lentivirus Gene Engineering Protocols, 135–47. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60761-533-0_9.
Pełny tekst źródłaCui, Yan, i Lung-Ji Chang. "Detection and Selection of Lentiviral Vector-Transduced Cells". W Lentivirus Gene Engineering Protocols, 69–85. Totowa, NJ: Humana Press, 2003. http://dx.doi.org/10.1385/1-59259-393-3:69.
Pełny tekst źródłaScherr, Michaela, Letizia Venturini i Matthias Eder. "Lentiviral Vector-Mediated Expression of pre-miRNAs and AntagomiRs". W Lentivirus Gene Engineering Protocols, 175–85. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60761-533-0_12.
Pełny tekst źródłater Brake, Olivier, Jan-Tinus Westerink i Ben Berkhout. "Lentiviral Vector Engineering for Anti-HIV RNAi Gene Therapy". W Lentivirus Gene Engineering Protocols, 201–13. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60761-533-0_14.
Pełny tekst źródłaDu, Zhong-Wei, i Su-Chun Zhang. "Lentiviral Vector-Mediated Transgenesis in Human Embryonic Stem Cells". W Lentivirus Gene Engineering Protocols, 127–34. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60761-533-0_8.
Pełny tekst źródłaVerhoeyen, Els, Caroline Costa i Francois-Loic Cosset. "Lentiviral Vector Gene Transfer into Human T Cells". W Genetic Modification of Hematopoietic Stem Cells, 97–114. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-409-4_8.
Pełny tekst źródłaStreszczenia konferencji na temat "Lentiviral vector"
Ranzani, Marco, Daniela Cesana, Cynthia C. Bartholomä, Francesca Sanvito, Michela Riba, Mauro Pala, Fabrizio Benedicenti i in. "Abstract 3169: Lentiviral vector-based insertional mutagenesis identifies new clinically relevant liver cancer genes." W Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3169.
Pełny tekst źródłaAlbershardt, Tina C., David J. Campbell, Andrea J. Parsons, Jan H. ter Meulen i Peter Berglund. "Abstract 2506: Preclinical characterization of LV305, a lentiviral vector targeting tumors expressing NY-ESO-1". W Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2506.
Pełny tekst źródłaDwivedi, Alka, Ling Su, Justin Mirazee, Mehdi Benzaoui, Christopher Chien, Nirali Shah, Xiaolin Wu i Naomi Taylor. "327 Clonal expansion of CD22 CAR T-cells following lentiviral vector integration in the PWWP3A gene". W SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0327.
Pełny tekst źródłaQin, Shi, i Jie Wang. "The construction of RGD-TAT-KDR siRNA fusion gene lentiviral vector and the study of its antitumor activityin vitro". W International Conference on Medical Engineering and Bioinformatics. Southampton, UK: WIT Press, 2014. http://dx.doi.org/10.2495/meb140171.
Pełny tekst źródłaBajaj, Anshika, Tsai-Yu Lin, Lisa Y. Ngo, Michele Murphy, Brenna Kelley-Clarke, Wayne R. Gombotz, Jan H. ter Meulen i Peter Berglund. "Abstract 5919: Component-specific qPCR assays for characterization and identity testing of multigenome ZVex®, a dendritic cell-targeting lentiviral vector platform". W Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5919.
Pełny tekst źródłaBajaj, Anshika, Lisa Y. Ngo, Peter Berglund i Jan ter Meulen. "Abstract 5092: ZVex® lentiviral vector strongly activates pro-inflammatory, antigen processing, and anti-viral defense response pathways in monocyte-derived dendritic cells". W Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-5092.
Pełny tekst źródłaRanzani, Marco, Daniela Cesana, Cynthia Bartholomae, Francesca Sanvito, Mauro Pala, Fabrizio Benedicenti, Lucia Sergi Sergi i in. "Abstract 4982: Identification of new human liver cancer genes by a novel lentiviral vector-based insertional mutagenesis approach in three mouse models of hepatocarcinogenesis". W Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4982.
Pełny tekst źródłaRanzani, Marco, Daniela Cesana, Cynthia C. Bartholomae, Francesca Sanvito, Mauro Pala, Fabrizio Benedicenti, Pierangela Gallina i in. "Abstract 104: New liver cancer genes identified by lentiviral vector-based insertional mutagenesis in mice are associated to differential survival in hepatocellular carcinoma patients". W Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-104.
Pełny tekst źródłaBryson, Paul D., Xiaolu Han, Norman Truong i Pin Wang. "Abstract 2888: Dendritic cell-targeted lentiviral vector vaccines overcome tolerance to generate a protective T-cell immune response to breast cancer antigens ERBB2 and α-lactalbumin". W Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-2888.
Pełny tekst źródłaNicolai, Chris, Jim Qin, Way Wu, Mollie McDonnell, Erica Shirazi, Greyson Hamilton, Max Chen i in. "1230 VivoVec lentiviral vector particles surface-engineered with T cell activating and co-stimulatory ligands enhancein vivoCAR T cell generation and antitumor activity". W SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.1230.
Pełny tekst źródłaRaporty organizacyjne na temat "Lentiviral vector"
Yes, Jiing-Kuan. Anti-Angiogenic Gene Therapy of Prostate Cancer with Lentiviral Vectors. Fort Belvoir, VA: Defense Technical Information Center, lipiec 2004. http://dx.doi.org/10.21236/ada428533.
Pełny tekst źródłaYee, Jiing-Kuan. Anti-Angiogenic Gene Therapy of Prostate Cancer With Lentiviral Vectors. Fort Belvoir, VA: Defense Technical Information Center, lipiec 2002. http://dx.doi.org/10.21236/ada410315.
Pełny tekst źródłaYee, Jiing-Kuan. Anti-Angiogenic Gene Therapy of Prostate Cancer with Lentiviral Vectors. Fort Belvoir, VA: Defense Technical Information Center, lipiec 2003. http://dx.doi.org/10.21236/ada418264.
Pełny tekst źródła